Comparative Pharmacology
Head-to-head clinical analysis: ALPRAZOLAM versus FOVANE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALPRAZOLAM versus FOVANE.
ALPRAZOLAM vs FOVANE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Positive allosteric modulator of GABA-A receptors; enhances GABA inhibitory neurotransmission by binding to benzodiazepine site on GABA-A receptor, increasing chloride ion conductance.
Selective serotonin reuptake inhibitor (SSRI); potentiates serotonergic activity by inhibiting reuptake of serotonin at the synaptic cleft.
0.25-0.5 mg orally 3 times daily; maximum 4 mg/day in divided doses.
Adults: 10 mg orally twice daily.
None Documented
None Documented
12-15 hours (mean ~13 hours); prolonged in elderly (up to 19 hours) and hepatic impairment (up to 20-30 hours); clinical context: allows once- to twice-daily dosing, but risk of accumulation with high doses or in vulnerable populations
Clinical Note
moderateAlprazolam + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Alprazolam is combined with Fluticasone propionate."
Clinical Note
moderateAlprazolam + Haloperidol
"The risk or severity of adverse effects can be increased when Alprazolam is combined with Haloperidol."
Clinical Note
moderateAlprazolam + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Alprazolam."
Clinical Note
moderateAlprazolam + Erythromycin
Terminal half-life: 12-15 hours; clinical context: supports twice-daily dosing, steady-state achieved by day 3.
Renal (approximately 80% as metabolites, <20% unchanged); fecal (minor, ~7%)
Renal: 60% unchanged; fecal: 30% (as metabolites); biliary: 10%.
Category D/X
Category C
Benzodiazepine
Benzodiazepine
"The serum concentration of Erythromycin can be increased when it is combined with Alprazolam."